{"id":1466,"date":"2025-10-20T11:34:44","date_gmt":"2025-10-20T09:34:44","guid":{"rendered":"https:\/\/www.sunrockbiopharma.com\/?p=1466"},"modified":"2025-10-20T11:34:44","modified_gmt":"2025-10-20T09:34:44","slug":"sunrock-biopharma-y-chime-biologics-anuncian-colaboracion-estrategica-para-impulsar-el-desarrollo-del-anticuerpo-anti-ccr9-srb5","status":"publish","type":"post","link":"https:\/\/www.sunrockbiopharma.com\/es\/sunrock-biopharma-y-chime-biologics-anuncian-colaboracion-estrategica-para-impulsar-el-desarrollo-del-anticuerpo-anti-ccr9-srb5\/","title":{"rendered":"SunRock Biopharma y Chime Biologics anuncian colaboraci\u00f3n estrat\u00e9gica para impulsar el desarrollo del anticuerpo anti-CCR9 SRB5"},"content":{"rendered":"<p data-start=\"306\" data-end=\"852\"><strong data-start=\"306\" data-end=\"377\">Santiago de Compostela (Espa\u00f1a) \/ Wuhan (China), septiembre de 2025<\/strong> \u2014 SunRock Biopharma, compa\u00f1\u00eda biotecnol\u00f3gica espa\u00f1ola especializada en el desarrollo de anticuerpos terap\u00e9uticos de nueva generaci\u00f3n, y Chime Biologics, organizaci\u00f3n CDMO l\u00edder a nivel mundial en desarrollo y producci\u00f3n de biol\u00f3gicos, han anunciado un acuerdo estrat\u00e9gico para el desarrollo de <strong data-start=\"672\" data-end=\"680\">SRB5<\/strong>, un innovador anticuerpo monoclonal anti-CCR9 dirigido a enfermedades inflamatorias intestinales (EII), con posible aplicaci\u00f3n futura en otras patolog\u00edas inmunomediadas.<\/p>\n<p data-start=\"854\" data-end=\"1455\">SRB5 es un anticuerpo monoclonal humanizado con propiedades mejoradas de ADCC, dise\u00f1ado para eliminar de forma selectiva las c\u00e9lulas CCR9+ implicadas en la inflamaci\u00f3n intestinal cr\u00f3nica. Se trata de la incorporaci\u00f3n m\u00e1s reciente a la plataforma anti-CCR9 de SunRock y supone un avance relevante en el enfoque terap\u00e9utico selectivo frente a enfermedades como la <strong data-start=\"1216\" data-end=\"1261\">enfermedad de Crohn y la colitis ulcerosa<\/strong>.<br data-start=\"1262\" data-end=\"1265\" \/>Gracias a esta alianza, SunRock podr\u00e1 apoyarse en la plataforma de fabricaci\u00f3n GMP de Chime Biologics para escalar la producci\u00f3n y acelerar hitos clave en fases precl\u00ednicas y regulatorias.<\/p>\n<p data-start=\"1457\" data-end=\"1516\">El Dr. Jimmy Wei, presidente de Chime Biologics, destac\u00f3:<\/p>\n<p data-start=\"1519\" data-end=\"2095\">\u201cNos enorgullece colaborar con SunRock Biopharma en este prometedor anticuerpo anti-CCR9 (SRB5) para las enfermedades inflamatorias intestinales, que afectan de manera significativa a pacientes en todo el mundo. Este acuerdo refleja nuestro compromiso de aportar nuestra experiencia y est\u00e1ndares de calidad global en la producci\u00f3n de biol\u00f3gicos para acelerar el desarrollo de terapias innovadoras. Confiamos en contribuir a la misi\u00f3n a largo plazo de SunRock de desarrollar anticuerpos innovadores contra tumores altamente invasivos con gran necesidad cl\u00ednica en oncolog\u00eda.\u201d<\/p>\n<p data-start=\"2097\" data-end=\"2169\">Por su parte, el Dr. Laureano Sim\u00f3n, CEO de SunRock Biopharma, a\u00f1adi\u00f3:<\/p>\n<p data-start=\"2172\" data-end=\"2653\">\u201cEsta colaboraci\u00f3n con Chime Biologics refuerza nuestra estrategia de trabajar con socios de primer nivel en todas las etapas de desarrollo. La experiencia t\u00e9cnica y la calidad industrial de Chime nos permitir\u00e1n escalar SRB5 en condiciones \u00f3ptimas. SRB5 presenta un perfil biol\u00f3gico diferencial que podr\u00eda transformar el abordaje terap\u00e9utico en EII y, potencialmente, en tumores agresivos con expresi\u00f3n de CCR9. Este acuerdo representa un paso clave hacia la validaci\u00f3n cl\u00ednica.\u201d<\/p>\n<hr data-start=\"2655\" data-end=\"2658\" \/>\n<h3 data-start=\"2660\" data-end=\"2688\">Sobre SunRock Biopharma<\/h3>\n<p data-start=\"2689\" data-end=\"3187\">SunRock Biopharma es una compa\u00f1\u00eda biotecnol\u00f3gica espa\u00f1ola dedicada al desarrollo de anticuerpos terap\u00e9uticos de primera clase, dirigidos a dianas validadas cl\u00ednica o emergentes en oncolog\u00eda y enfermedades inflamatorias inmunomediadas. Su estrategia se centra en identificar objetivos clave en la progresi\u00f3n tumoral o inflamatoria, generar anticuerpos humanos o humanizados con perfiles funcionales mejorados y llevarlos a fases cl\u00ednicas tempranas para su licencia a farmac\u00e9uticas internacionales.<\/p>\n<p data-start=\"3189\" data-end=\"3547\">El pipeline de SunRock incluye anticuerpos monoclonales, conjugados anticuerpo-f\u00e1rmaco (ADCs) y otros formatos innovadores. Bajo un modelo de innovaci\u00f3n abierta, colabora con universidades y socios industriales en Europa, EE. UU. y Asia. Su objetivo es otorgar licencias de sus desarrollos tras demostrar una s\u00f3lida validaci\u00f3n precl\u00ednica y cl\u00ednica inicial.<\/p>\n<p data-start=\"3549\" data-end=\"3627\">M\u00e1s informaci\u00f3n: <a class=\"decorated-link\" href=\"http:\/\/www.sunrockbiopharma.com\" target=\"_new\" rel=\"noopener\" data-start=\"3566\" data-end=\"3625\">www.sunrockbiopharma.com<\/a><\/p>\n<hr data-start=\"4392\" data-end=\"4395\" \/>\n<p data-start=\"4397\" data-end=\"4470\"><strong data-start=\"4397\" data-end=\"4439\">Contacto de prensa \u2013 SunRock Biopharma<\/strong><br data-start=\"4439\" data-end=\"4442\" \/><a class=\"decorated-link cursor-pointer\" rel=\"noopener\" data-start=\"4442\" data-end=\"4468\">media@sunrockbiopharma.com<\/a><\/p>\n<p data-start=\"4397\" data-end=\"4470\"><strong data-start=\"4472\" data-end=\"4512\">Contacto de prensa \u2013 Chime Biologics<\/strong><br data-start=\"4512\" data-end=\"4515\" \/><a class=\"decorated-link cursor-pointer\" rel=\"noopener\" data-start=\"4515\" data-end=\"4538\">info@chimebiologics.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Santiago de Compostela (Espa\u00f1a) \/ Wuhan (China), septiembre de 2025 \u2014 SunRock Biopharma, compa\u00f1\u00eda biotecnol\u00f3gica espa\u00f1ola especializada en el desarrollo de&#8230;<\/p>\n","protected":false},"author":1,"featured_media":1463,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mi_skip_tracking":false},"categories":[19],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v17.7.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\r\n<title>SunRock Biopharma y Chime Biologics anuncian colaboraci\u00f3n estrat\u00e9gica para impulsar el desarrollo del anticuerpo anti-CCR9 SRB5 | SunRock Biopharma<\/title>\r\n<meta name=\"robots\" content=\"noindex, follow\" \/>\r\n<meta property=\"og:locale\" content=\"es_ES\" \/>\r\n<meta property=\"og:type\" content=\"article\" \/>\r\n<meta property=\"og:title\" content=\"SunRock Biopharma y Chime Biologics anuncian colaboraci\u00f3n estrat\u00e9gica para impulsar el desarrollo del anticuerpo anti-CCR9 SRB5 | SunRock Biopharma\" \/>\r\n<meta property=\"og:description\" content=\"Santiago de Compostela (Espa\u00f1a) \/ Wuhan (China), septiembre de 2025 \u2014 SunRock Biopharma, compa\u00f1\u00eda biotecnol\u00f3gica espa\u00f1ola especializada en el desarrollo de...\" \/>\r\n<meta property=\"og:url\" content=\"https:\/\/www.sunrockbiopharma.com\/es\/sunrock-biopharma-y-chime-biologics-anuncian-colaboracion-estrategica-para-impulsar-el-desarrollo-del-anticuerpo-anti-ccr9-srb5\/\" \/>\r\n<meta property=\"og:site_name\" content=\"SunRock Biopharma\" \/>\r\n<meta property=\"article:published_time\" content=\"2025-10-20T09:34:44+00:00\" \/>\r\n<meta property=\"og:image\" content=\"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2025\/10\/SR-Chime-2.png\" \/>\r\n\t<meta property=\"og:image:width\" content=\"1668\" \/>\r\n\t<meta property=\"og:image:height\" content=\"1409\" \/>\r\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\r\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"SunRock\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\r\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.sunrockbiopharma.com\/#organization\",\"name\":\"SunRock Biopharma\",\"url\":\"https:\/\/www.sunrockbiopharma.com\/\",\"sameAs\":[],\"logo\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/www.sunrockbiopharma.com\/#logo\",\"inLanguage\":\"es\",\"url\":\"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2020\/09\/sunrock-seo-fb.png\",\"contentUrl\":\"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2020\/09\/sunrock-seo-fb.png\",\"width\":1201,\"height\":631,\"caption\":\"SunRock Biopharma\"},\"image\":{\"@id\":\"https:\/\/www.sunrockbiopharma.com\/#logo\"}},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.sunrockbiopharma.com\/#website\",\"url\":\"https:\/\/www.sunrockbiopharma.com\/\",\"name\":\"SunRock Biopharma\",\"description\":\"Solutions for cancer therapy\",\"publisher\":{\"@id\":\"https:\/\/www.sunrockbiopharma.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.sunrockbiopharma.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/www.sunrockbiopharma.com\/es\/sunrock-biopharma-y-chime-biologics-anuncian-colaboracion-estrategica-para-impulsar-el-desarrollo-del-anticuerpo-anti-ccr9-srb5\/#primaryimage\",\"inLanguage\":\"es\",\"url\":\"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2025\/10\/SR-Chime-2.png\",\"contentUrl\":\"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2025\/10\/SR-Chime-2.png\",\"width\":1668,\"height\":1409},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.sunrockbiopharma.com\/es\/sunrock-biopharma-y-chime-biologics-anuncian-colaboracion-estrategica-para-impulsar-el-desarrollo-del-anticuerpo-anti-ccr9-srb5\/#webpage\",\"url\":\"https:\/\/www.sunrockbiopharma.com\/es\/sunrock-biopharma-y-chime-biologics-anuncian-colaboracion-estrategica-para-impulsar-el-desarrollo-del-anticuerpo-anti-ccr9-srb5\/\",\"name\":\"SunRock Biopharma y Chime Biologics anuncian colaboraci\\u00f3n estrat\\u00e9gica para impulsar el desarrollo del anticuerpo anti-CCR9 SRB5 | SunRock Biopharma\",\"isPartOf\":{\"@id\":\"https:\/\/www.sunrockbiopharma.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.sunrockbiopharma.com\/es\/sunrock-biopharma-y-chime-biologics-anuncian-colaboracion-estrategica-para-impulsar-el-desarrollo-del-anticuerpo-anti-ccr9-srb5\/#primaryimage\"},\"datePublished\":\"2025-10-20T09:34:44+00:00\",\"dateModified\":\"2025-10-20T09:34:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.sunrockbiopharma.com\/es\/sunrock-biopharma-y-chime-biologics-anuncian-colaboracion-estrategica-para-impulsar-el-desarrollo-del-anticuerpo-anti-ccr9-srb5\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.sunrockbiopharma.com\/es\/sunrock-biopharma-y-chime-biologics-anuncian-colaboracion-estrategica-para-impulsar-el-desarrollo-del-anticuerpo-anti-ccr9-srb5\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.sunrockbiopharma.com\/es\/sunrock-biopharma-y-chime-biologics-anuncian-colaboracion-estrategica-para-impulsar-el-desarrollo-del-anticuerpo-anti-ccr9-srb5\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.sunrockbiopharma.com\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SunRock Biopharma y Chime Biologics anuncian colaboraci\\u00f3n estrat\\u00e9gica para impulsar el desarrollo del anticuerpo anti-CCR9 SRB5\"}]},{\"@type\":\"Article\",\"@id\":\"https:\/\/www.sunrockbiopharma.com\/es\/sunrock-biopharma-y-chime-biologics-anuncian-colaboracion-estrategica-para-impulsar-el-desarrollo-del-anticuerpo-anti-ccr9-srb5\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.sunrockbiopharma.com\/es\/sunrock-biopharma-y-chime-biologics-anuncian-colaboracion-estrategica-para-impulsar-el-desarrollo-del-anticuerpo-anti-ccr9-srb5\/#webpage\"},\"author\":{\"@id\":\"https:\/\/www.sunrockbiopharma.com\/#\/schema\/person\/4ea2f25ba0ae14f007cd36bc8c8550ea\"},\"headline\":\"SunRock Biopharma y Chime Biologics anuncian colaboraci\\u00f3n estrat\\u00e9gica para impulsar el desarrollo del anticuerpo anti-CCR9 SRB5\",\"datePublished\":\"2025-10-20T09:34:44+00:00\",\"dateModified\":\"2025-10-20T09:34:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.sunrockbiopharma.com\/es\/sunrock-biopharma-y-chime-biologics-anuncian-colaboracion-estrategica-para-impulsar-el-desarrollo-del-anticuerpo-anti-ccr9-srb5\/#webpage\"},\"wordCount\":547,\"publisher\":{\"@id\":\"https:\/\/www.sunrockbiopharma.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.sunrockbiopharma.com\/es\/sunrock-biopharma-y-chime-biologics-anuncian-colaboracion-estrategica-para-impulsar-el-desarrollo-del-anticuerpo-anti-ccr9-srb5\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2025\/10\/SR-Chime-2.png\",\"articleSection\":[\"noticias\"],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.sunrockbiopharma.com\/#\/schema\/person\/4ea2f25ba0ae14f007cd36bc8c8550ea\",\"name\":\"SunRock\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/www.sunrockbiopharma.com\/#personlogo\",\"inLanguage\":\"es\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e49e14e1d27c5f474f91bf5035dbde13?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e49e14e1d27c5f474f91bf5035dbde13?s=96&d=mm&r=g\",\"caption\":\"SunRock\"}}]}<\/script>\r\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SunRock Biopharma y Chime Biologics anuncian colaboraci\u00f3n estrat\u00e9gica para impulsar el desarrollo del anticuerpo anti-CCR9 SRB5 | SunRock Biopharma","robots":{"index":"noindex","follow":"follow"},"og_locale":"es_ES","og_type":"article","og_title":"SunRock Biopharma y Chime Biologics anuncian colaboraci\u00f3n estrat\u00e9gica para impulsar el desarrollo del anticuerpo anti-CCR9 SRB5 | SunRock Biopharma","og_description":"Santiago de Compostela (Espa\u00f1a) \/ Wuhan (China), septiembre de 2025 \u2014 SunRock Biopharma, compa\u00f1\u00eda biotecnol\u00f3gica espa\u00f1ola especializada en el desarrollo de...","og_url":"https:\/\/www.sunrockbiopharma.com\/es\/sunrock-biopharma-y-chime-biologics-anuncian-colaboracion-estrategica-para-impulsar-el-desarrollo-del-anticuerpo-anti-ccr9-srb5\/","og_site_name":"SunRock Biopharma","article_published_time":"2025-10-20T09:34:44+00:00","og_image":[{"width":1668,"height":1409,"url":"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2025\/10\/SR-Chime-2.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"SunRock","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Organization","@id":"https:\/\/www.sunrockbiopharma.com\/#organization","name":"SunRock Biopharma","url":"https:\/\/www.sunrockbiopharma.com\/","sameAs":[],"logo":{"@type":"ImageObject","@id":"https:\/\/www.sunrockbiopharma.com\/#logo","inLanguage":"es","url":"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2020\/09\/sunrock-seo-fb.png","contentUrl":"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2020\/09\/sunrock-seo-fb.png","width":1201,"height":631,"caption":"SunRock Biopharma"},"image":{"@id":"https:\/\/www.sunrockbiopharma.com\/#logo"}},{"@type":"WebSite","@id":"https:\/\/www.sunrockbiopharma.com\/#website","url":"https:\/\/www.sunrockbiopharma.com\/","name":"SunRock Biopharma","description":"Solutions for cancer therapy","publisher":{"@id":"https:\/\/www.sunrockbiopharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sunrockbiopharma.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"ImageObject","@id":"https:\/\/www.sunrockbiopharma.com\/es\/sunrock-biopharma-y-chime-biologics-anuncian-colaboracion-estrategica-para-impulsar-el-desarrollo-del-anticuerpo-anti-ccr9-srb5\/#primaryimage","inLanguage":"es","url":"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2025\/10\/SR-Chime-2.png","contentUrl":"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2025\/10\/SR-Chime-2.png","width":1668,"height":1409},{"@type":"WebPage","@id":"https:\/\/www.sunrockbiopharma.com\/es\/sunrock-biopharma-y-chime-biologics-anuncian-colaboracion-estrategica-para-impulsar-el-desarrollo-del-anticuerpo-anti-ccr9-srb5\/#webpage","url":"https:\/\/www.sunrockbiopharma.com\/es\/sunrock-biopharma-y-chime-biologics-anuncian-colaboracion-estrategica-para-impulsar-el-desarrollo-del-anticuerpo-anti-ccr9-srb5\/","name":"SunRock Biopharma y Chime Biologics anuncian colaboraci\u00f3n estrat\u00e9gica para impulsar el desarrollo del anticuerpo anti-CCR9 SRB5 | SunRock Biopharma","isPartOf":{"@id":"https:\/\/www.sunrockbiopharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sunrockbiopharma.com\/es\/sunrock-biopharma-y-chime-biologics-anuncian-colaboracion-estrategica-para-impulsar-el-desarrollo-del-anticuerpo-anti-ccr9-srb5\/#primaryimage"},"datePublished":"2025-10-20T09:34:44+00:00","dateModified":"2025-10-20T09:34:44+00:00","breadcrumb":{"@id":"https:\/\/www.sunrockbiopharma.com\/es\/sunrock-biopharma-y-chime-biologics-anuncian-colaboracion-estrategica-para-impulsar-el-desarrollo-del-anticuerpo-anti-ccr9-srb5\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sunrockbiopharma.com\/es\/sunrock-biopharma-y-chime-biologics-anuncian-colaboracion-estrategica-para-impulsar-el-desarrollo-del-anticuerpo-anti-ccr9-srb5\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.sunrockbiopharma.com\/es\/sunrock-biopharma-y-chime-biologics-anuncian-colaboracion-estrategica-para-impulsar-el-desarrollo-del-anticuerpo-anti-ccr9-srb5\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sunrockbiopharma.com\/es\/"},{"@type":"ListItem","position":2,"name":"SunRock Biopharma y Chime Biologics anuncian colaboraci\u00f3n estrat\u00e9gica para impulsar el desarrollo del anticuerpo anti-CCR9 SRB5"}]},{"@type":"Article","@id":"https:\/\/www.sunrockbiopharma.com\/es\/sunrock-biopharma-y-chime-biologics-anuncian-colaboracion-estrategica-para-impulsar-el-desarrollo-del-anticuerpo-anti-ccr9-srb5\/#article","isPartOf":{"@id":"https:\/\/www.sunrockbiopharma.com\/es\/sunrock-biopharma-y-chime-biologics-anuncian-colaboracion-estrategica-para-impulsar-el-desarrollo-del-anticuerpo-anti-ccr9-srb5\/#webpage"},"author":{"@id":"https:\/\/www.sunrockbiopharma.com\/#\/schema\/person\/4ea2f25ba0ae14f007cd36bc8c8550ea"},"headline":"SunRock Biopharma y Chime Biologics anuncian colaboraci\u00f3n estrat\u00e9gica para impulsar el desarrollo del anticuerpo anti-CCR9 SRB5","datePublished":"2025-10-20T09:34:44+00:00","dateModified":"2025-10-20T09:34:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.sunrockbiopharma.com\/es\/sunrock-biopharma-y-chime-biologics-anuncian-colaboracion-estrategica-para-impulsar-el-desarrollo-del-anticuerpo-anti-ccr9-srb5\/#webpage"},"wordCount":547,"publisher":{"@id":"https:\/\/www.sunrockbiopharma.com\/#organization"},"image":{"@id":"https:\/\/www.sunrockbiopharma.com\/es\/sunrock-biopharma-y-chime-biologics-anuncian-colaboracion-estrategica-para-impulsar-el-desarrollo-del-anticuerpo-anti-ccr9-srb5\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2025\/10\/SR-Chime-2.png","articleSection":["noticias"],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/www.sunrockbiopharma.com\/#\/schema\/person\/4ea2f25ba0ae14f007cd36bc8c8550ea","name":"SunRock","image":{"@type":"ImageObject","@id":"https:\/\/www.sunrockbiopharma.com\/#personlogo","inLanguage":"es","url":"https:\/\/secure.gravatar.com\/avatar\/e49e14e1d27c5f474f91bf5035dbde13?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e49e14e1d27c5f474f91bf5035dbde13?s=96&d=mm&r=g","caption":"SunRock"}}]}},"_links":{"self":[{"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/posts\/1466"}],"collection":[{"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/comments?post=1466"}],"version-history":[{"count":4,"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/posts\/1466\/revisions"}],"predecessor-version":[{"id":1470,"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/posts\/1466\/revisions\/1470"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/media\/1463"}],"wp:attachment":[{"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/media?parent=1466"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/categories?post=1466"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/tags?post=1466"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}